^
Association details:
| Biomarker: | ERCC1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer
Published date:
10/20/2022
Excerpt:
The aim of the pan-cancers analysis was to study the effect of ERCC1 expression on immune responses to identify patients with different types of cancers that may benefit from anti-ERCC1 immunotherapy….Furthermore, a negative correlation was observed between ERCC1 expression and most immune checkpoints....High ERCC1 expression also influences the efficacy of immunotherapy and chemotherapy.
DOI:
10.3389/fonc.2022.955719
